|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||258.21 - 258.60|
|52-week range||258.21 - 258.60|
|Beta (5Y monthly)||1.45|
|PE ratio (TTM)||48.67|
|Earnings date||18 Oct 2021 - 22 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Encouraging yearly guidance and consecutive better-than-expected top- and bottom-line performances have been aiding IQVIA Holdings' (IQV) stock.
IQVIA (IQV) and NRx are set to work closely to support activities essential for emergency use authorization of ZYESAMI.
RESEARCH TRIANGLE PARK, N.C., September 13, 2021--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx) (Nasdaq: NRXP). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited